CANAQUEST MEDICAL CORP (OTCPK:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system, announced statistically significant efficacy results from the clinical dose and efficacy study conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.

Highlights derived from the study are as follows:

• The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.

• These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (phase II/III, double-blind trial, 60 patients).

• CanaQuest has identified the regulatory pathways to obtain Rx drug identification numbers in Canada and the USA for epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.

"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," stated Burnham, pharmacologist and co-director of EpLink.

Paul Ramsay, president, stated, "The clinical study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."

Get your daily dose of cannabis news on Benzinga Cannabis. Don't miss out on any important developments in the industry.

Photo by Jeff W on Unsplash